Panel: Tafamidis data predictive of benefit, but efficacy evidence not robust
This article was originally published in Scrip
A panel of advisers to the US FDA on 24 May did not find substantial evidence of efficacy on a clinical endpoint in Pfizer's single study of its experimental drug tafamidis meglumine in treating transthyretin familial amyloid polyneuropathy (TTR-FAP), but said the data were strong enough to match what might be found by a surrogate endpoint likely to predict a clinical benefit.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.